Allschwil, Switzerland, April 17, 2019
- Murepavadin to be more potent than standard of care anti-Pseudomonas antibiotics against multidrug and colistin resistant Pseudomonas aeruginosa isolates
- Clinical development candidate POL7306 demonstrates potent bactericidal activity against a large collection of Gram-negative organisms including WHO priority 1 Gram-negative pathogens and shows a low propensity of resistance development invitro.
Polyphor AG (SIX: POLN) presented new data on its lead clinical antibacterial candidate, murepavadin, currently in Phase III, and its preclinical medium-spectrum anti Gram-negative antibiotic POL7306 at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands.
Full PR available here